🏅 FDA Orphan Designation
Farydak
panobinostat
Manufacturer: zr pharma& GmbH
Indicated for:
Multiple myelomaOrphan
FDA-Approved Indications (1)
Multiple myelomaOrphan Designation
FARYDAK (panobinostat) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomi…
Indications & Usage
FARYDAK (panobinostat) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent
💙 Support Programs
View all →Farydak
zr pharma& GmbH
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.